Immunology Phase 3 Deal Benchmarks — Europe (2026)

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $634M to $1.1B, with a median of $880M. Royalty rates for immunology assets at this stage typically fall between 12.2% and 19% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Europe territory applies a 0.25x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating europe rights should calibrate upfront expectations and milestone structures accordingly.